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Abstract 
Tissue engineering technologies, which have originally been designed to reconstitute 
damaged tissue structure and function, can mimic not only tissue regeneration processes but 
also cancer development and progression. Bioengineered approaches allow cell biologists to 
develop sophisticated experimentally and physiologically relevant cancer models to 
recapitulate the complexity of the disease seen in patients. Tissue engineering tools enable 
three-dimensionality based on the design of biomaterials and scaffolds that re-create the 
geometry, chemistry, function and signalling milieu of the native tumour microenvironment. 
Three-dimensional (3D) microenvironments, including cell-derived matrices, biomaterial-
based cell culture models and integrated co-cultures with engineered stromal components, are 
powerful tools to study dynamic processes like proteolytic functions associated with cancer 
progression, metastasis and resistance to therapeutics. In this review, we discuss how 
biomimetic strategies can reproduce a humanised niche for human cancer cells, such as 
peritoneal or bone-like microenvironments, addressing specific aspects of ovarian and 
prostate cancer progression and therapy response. 
3 
1. Introduction 
Since the collective vision of its early pioneers Robert Langer and Joseph Vacanti, the main 
purpose of tissue engineering was to restore, maintain and improve the function of a wide 
range of human tissues by combining principles of biology and engineering [1-3]. The 
concept of tumour tissue engineering on the other hand is still in its infancy but holds great 
promise. Over the last decade, advances in molecular and cellular biology have shown that 
the mutual interactions between extracellular matrix (ECM) components and cancer cells are 
bidirectional and signals from the local microenvironment, or niche, are critical for tumour 
progression and metastasis [4]. Although a series of genetic and epigenetic alterations of 
single cells may be necessary for carcinogenesis, the paradigm that cancer is a cellular 
disease defined only by these alterations has been left in favour to one in which the disease 
harbours a dynamic multistep process initiated and maintained by interactions between 
malignant and non-malignant cells. 
This niche concept is not new and has already been postulated in a similar, although 
metaphorical way, by Stephen Paget in 1889: ‘... Every single cancer cell must be regarded as 
an organism, alive and capable of development. When a plant goes to seed, its seeds are 
carried in all directions, but can only live and grow if they fall on congenial soil ...’ [5, 6]. A 
fortiori, it is remarkable that the vast majority of experimental studies, particularly in the 
cancer community, still apply conventional two-dimensional (2D) approaches for drug 
screening. Such suboptimal systems might result in misleading observations and hypotheses 
[7-9]. Although it is well known that structural variables and signalling from the three-
dimensional (3D) tumour microenvironment alter the phenotype, invasiveness and drug 
resistance of cancer cells, this fact is mostly ignored in traditional cell monolayer (2D) 
experiments [10-12]. 
Tissue engineering strategies can overcome these limitations and provide a potent tool box 
for cancer research by in vitro or in vivo modelling of the 3D tumour microenvironment [13, 
14]. It is still a long road to re-create the molecular architecture of the human cancer cell 
niche one to one and the dynamic mechanisms of the signalling milieu between ECM 
components and cancer cells. Nevertheless, mimicking these complex physiological 
phenomena under reproducible conditions allows a more reliable preclinical evaluation of 
anti-cancer drug candidates (Figure 1). 
In the following review, we will provide an overview of bioengineered in vitro and in vivo 
models that are suitable to recapitulate the interactions between the tumour and its 
microenvironment. The main focus will lie on ovarian and prostate cancer progression as our 
group is currently developing several engineered models for both tumour entities [15-24]. 
 
2. Clinical features of ovarian and prostate cancer 
Ovarian cancer accounts only for 3% of all incident cancer cases among women per year, 
while prostate cancer is the most common cancer with 29% of all incident cancer cases in 
men, with an estimated cancer death rate of 5% and 10% respectively in the United States. 
Ovarian cancer has the highest mortality rate of all gynaecological malignancies of the 
reproductive system, with a 5-year relative survival rate of 30%. Prostate cancer is the most 
commonly diagnosed malignancy in males and the second leading cause of male cancer 
deaths [25]. Epidemiological studies focusing on the initiation of prostate cancer and its 
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potential for progression have revealed a high dependency on racial disparity and nationality, 
suggesting the importance of early lifestyle, environmental and exogenous carcinogenic 
parameters [26]. Initially, most patients with ovarian or prostate cancer respond to therapy 
(e.g. platinum- or taxane-based chemotherapy, hormone therapy), but eventually relapse 
occurs accompanied with resistance to therapy and re-initiation of tumour growth and 
formation of secondary lesions [27, 28]. There is still a strong need for more effective and 
targeted treatments for metastatic disease and to bypass mechanisms underlying drug 
resistance, which has been reviewed elsewhere [29, 30]. 
Within the next two sections the histological and molecular characteristics of the 
heterogeneity of ovarian and prostate cancer will be described leading to the design of 
various engineered experimental models to study their specific path of disease progression 
and therapy response. 
 
2.1. Ovarian cancer 
Ovarian cancer should not be regarded as a single entity, although its only unifying clinical 
feature is the loco-regional dissemination of cancer cells to the ovaries and related pelvic 
organs [31, 32]. This malignant disease comprises epithelial (>85%), sex cord-stromal (>5%) 
and germ cell ovarian tumours (>3%). Epithelial ovarian carcinoma are characterised by four 
morphological subtypes: serous, endometrioid, mucinous and clear cell ovarian 
adenocarcinoma. These are defined by their differentiation status, with high-grade serous 
ovarian carcinoma being the most frequent and lethal worldwide [33, 34]. The high mortality 
rate is primarily due to difficulties in sensitive screening of the early disease stages. This 
female malignancy is often described as a ‘silent killer’ due to its asymptomatic early disease 
stages, and hence, most patients are diagnosed at an advanced stage, with evidence of 
intraperitoneal tumour outgrowth beyond the ovary, presence of tumour fluid (ascites) and 
poor prognosis [35]. Initially, patients respond to a cytoreductive and debulking surgical 
approach and platinum- and taxane-based chemotherapy, but eventually chemoresistance 
occurs leading to a median progression-free survival rate of only 18 months [36, 37]. 
Developing improved therapeutic approaches in terms of a long-term cure has remained 
challenging as little is known about the underlying events promoting ovarian cancer 
progression, the tumour-stroma network and how chemoresistance occurs [37]. Early 
postoperative intraperitoneal therapy of patients with advanced disease has resulted in 
improved progression-free survival and overall survival compared to intravenous 
administration; however, toxicity associated with intraperitoneal treatment was considerably 
increased [38]. Drug-loaded tumour-penetrating micro-particles can provide an alternative 
intraperitoneal treatment regime for tumour-selective delivery and reduction of toxicity due 
to fast drug release as demonstrated in an ovarian cancer animal model [39]. Estrogen and 
progesterone receptor signalling is also partially involved in ovarian cancer progression, and 
both receptors are prognostic biomarkers for ovarian cancer. Whether the hormone receptor 
status can predict response to endocrine therapy, needs to be further studied [40]. 
 
2.2. Prostate cancer 
During prostate cancer development, one of the indispensable factors is androgen and 
androgen receptor (AR)-mediated signalling. In fact, anti-androgen therapy (e.g. 
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Bicalutamide, Enzalutamide) has become a standard care for advanced prostate cancer [28]. 
The management of localised adenocarcinoma of the prostate involves primarily two other 
options, external-beam radiation and radical prostatectomy [41]. These therapeutic strategies 
are highly successful and have resulted in improved survival rates of patients with localised 
disease. The prognosis of these patients is excellent with an overall 5-year survival rate of 
>90% [42]. However, after a median time of 12-33 months, a relapse is observed despite anti-
androgen therapy as noted above with castration-like levels of serum testosterone [43]. This 
hormone-refractory/androgen-insensitive status is referred to as castrate-resistant prostate 
cancer and is associated with disease progression subsequently leading to multiple 
metastases, most frequently involving the axial skeleton. To date, treatment options for 
patients with prostate cancer bone metastases are at best palliative resulting in a 5-year 
relative survival rate of <25% [44-46]. Metastatic bone disease causes some of the most 
distressing symptoms and complications in advanced prostate cancer, such as pathological 
fracture or spinal cord compression, which are also referred to as skeletal-related events, and 
are associated with poor prognosis [47]. Taxane-based chemotherapy in combination with 
corticosteroids became the standard of care in these patients but most of them develop a 
relapse within the first year of therapy [48]. This resistance to therapy might occur through 
genetic alterations and changes in the bone microenvironment leading to increased cancer cell 
survival and proliferation [49]. Therefore, several combinatorial microenvironment- and 
bone-targeted therapeutic strategies have been developed [50]. While agents like Denosumab 
or Bisphosphonates reduce the number of skeletal-related events, there are still no drug 
candidates available that significantly increase the overall survival of patients with metastatic 
disease. To better understand the molecular and cellular mechanisms of prostate cancer bone 
metastasis, novel engineered models are needed to mimic the disease seen in patients. A 
tissue-engineered in vitro bone model, using for example a 3D silk fibroin scaffold modified 
with a bone morphogenic protein (e.g. BMP2), can help to decipher the osteoblastic and 
osteolytic processes occurring during prostate cancer metastasis to bone [51]. 
 
3. Molecular characteristics of ovarian and prostate cancer 
The molecular biomarkers cancer antigen 125 (CA125, also known as mucin 16/MUC16) and 
prostate-specific antigen (PSA, also known as kallikrein-related peptidase 3/KLK3) are used 
to detect ovarian and prostate cancer respectively and to monitor response to therapy 
clinically. However, CA125 lacks specificity for screening of early stage, persistent and 
recurrent disease and results in one third of all cases in false negatives. The tumour-
associated expression of KLKs, in particular KLK5, and the human epididymis protein 4 
(HE4, WFDC2) are promising complementary biomarkers for ovarian cancer-expressed 
CA125 [52-56]. The presence of KLK5, KLK6 and KLK7 in ovarian cancer tissues showed a 
closer association with a large remaining tumour mass following surgery, high-grade and late 
stage disease than CA125 [57]. KLK6 expression, as per immunohistochemical and 
multivariate analyses, was correlated with the presence of stromal cells in cancerous tissue 
and shorter overall and progression-free survival of ovarian cancer patients [58]. KLK7 
levels, as determined by ELISA and multivariate analyses, were correlated with prolonged 
overall and progression-free survival of ovarian cancer patients [59]. Screening or rigorous 
clinical testing for circulating PSA has helped to achieve an overall 5-year survival rate for 
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prostate cancer of 99%; however, benign pathologies can also cause a non-specific release of 
PSA into the blood [60, 61]. PSA testing has also been shown to have a greater influence on 
incidence than on mortality [62]. This has generated considerable discussion about the 
benefits of early disease detection and aggressive therapeutic approaches in early localised 
prostate cancer [63, 64]. Other non-invasive diagnostic tools, such as disease-related 
circulating microRNAs (miRNA), are being currently clinically evaluated for the detection of 
ovarian and prostate cancer and predictors of therapy outcome [65, 66]. 
 
3.1. Molecular fingerprint of ovarian cancer 
Ovarian cancer develops de novo due to multiple genetic alterations, without identifiable 
precursor lesions, from different tissues of origin, such as the ovarian surface epithelium, 
abdominal peritoneum or distal fallopian tube [36, 67, 68]. Evidence for a potential fallopian 
tube origin has been provided [33], for example by complete sectioning of the fallopian tubes 
of patients with serous carcinoma [69, 70] and a double knockout animal model with a 
reproductive tract-specific deletion in the miRNA processing enzyme Dicer and the tumour 
suppressor PTEN [71]. As such, secretory epithelial cells from the fimbrial end can be used 
experimentally to study fallopian tube transformation during ovarian cancer development [32, 
72]. Another de novo animal model was genetically engineered to recapitulate the early 
disease stages by targeting commonly altered genes in secretory epithelial cells [73]. 
Epithelial ovarian cancer is not a single disease but is composed of a diverse group of 
tumours that can be classified based on their distinctive clinico-pathological heterogeneity. A 
two-pathway model of ovarian cancer has been postulated [74, 75]. Type I tumours are 
serous, endometrioid, mucinous, clear cell and borderline tumours displaying low-grade 
nuclear and architectural features, including slow growth and no TP53 mutations. Type II 
tumours comprise highly aggressive, rapidly growing carcinomas discovered at a late clinical 
stage, including high-grade serous carcinoma, undifferentiated carcinoma and malignant 
mixed mesodermal tumours, with TP53 mutations [69, 75-77]. The most common and 
malignant type of ovarian cancer, high-grade serous carcinoma (type II tumour), is 
characterised by frequent TP53 (>80%) and CCNE1 (30%) amplifications, while low-grade 
serous carcinoma (type I tumour) show KRAS (30%), BRAF (30%) or ERBB2 mutations. 
Most type I tumours harbour CTNNB1 (endometroid), PTEN (endometroid), PIK3CA 
(endometroid, clear cell) or KRAS (mucinous) mutations and are genetically more stable than 
type II tumours. Germline mutations of the tumour suppressor genes BRCA1 or BRCA2 are 
causative for the majority (>90%) of hereditary ovarian cancers [78, 79]. Additionally, a 
protein signature, including AR and members of the EGFR and MEK/ERK signalling 
cascade, for high-grade serous ovarian cancer has been developed and is correlated with the 
risk of disease recurrence, progression-free survival and overall survival time, and can, upon 
integration of genetic mutations, predict patient’s outcomes and opportunities for early 
therapeutic intervention [80]. These scientific advances on the molecular characterisation of 
ovarian cancer provide the translational foundation for such signatures to be integrated into 
clinical practice to improve patient care and to design personalised therapies for individual 
patients with greater selectivity and lower toxicity [81]. For example, patients with BRCA 
mutations respond better to platinum-based chemotherapy and may be highly susceptible to 
poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors that target the BRCA gene 
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[82-85]. A molecular signature of therapy resistance of patients diagnosed with advanced 
serous ovarian cancer has been postulated by comparing chemo-naive with chemo-resistant 
ascites-derived cells. Chemo-resistant cells had a more epithelial and cancer stem cell-like 
phenotype (e.g. high levels of the epithelial cell adhesion molecule (EpCaM), CA125, Oct4, 
STAT3) and were non-adherent in contrast to chemo-naive cells [86]. Platinum-based 
treatment induced a transition from an epithelial to mesenchymal expression profile in 
residual cancer cells accompanied with MAPK signalling, suggesting that phenotypical 
plasticity drives a cellular protection mechanism to escape the cytotoxic effects of 
chemotherapy [87]. 
 
3.2. Molecular fingerprint of prostate cancer 
Although it is widely accepted that prostatic intraepithelial neoplasia may represent a 
precursor lesion of prostate cancer [88], the processes that promote prostate carcinogenesis 
are still poorly understood. However, the development of prostate cancer is causally linked to 
gene expression changes associated with cellular senescence and inflammatory responses 
[89]. The vast majority (>95%) of malignant prostatic lesions are pathologically classified as 
adenocarcinomas [90], while other types, such as mucinous, neuroendocrine or signet ring 
carcinomas are extremely rare [91]. In contrast to ovarian cancer, there is a lack of 
pathologically defined subtypes that differ in their prognosis or response to therapeutic 
regimes. Nevertheless, recent studies have shown that molecular changes are associated with 
different stages of the disease which can help to determine the prognosis of patients with 
these markers in the future [92]. Down-regulation of the NKX3.1 homebox gene is a critical 
event in prostate cancer development and increases in frequency with cancer grade [93]. 
Despite the loss of the NKX3.1 locus, no mutations in the remaining allele have been detected 
[94]. Therefore, NKX3.1 seems to be a haplo-insufficient tumour suppressor gene that 
functions as ‘gatekeeper gene’ for prostate cancer development [95]. The MYC oncogene also 
plays an important role in prostate cancer initiation as it is over-expressed in prostatic 
intraepithelial neoplasias and carcinomas [96]. Several studies have identified chromosomal 
rearrangements that lead to an activation of transcription factors of the ETS family [97, 98]. 
One of these rearrangements results in the development of the TMPRSS2-ERG fusion gene in 
approximately 15% of intraepithelial neoplasias and 50% of prostate cancer, suggesting an 
early effect of the fusion gene on cancer development [99, 100]. A step towards cancer 
progression is the loss of PTEN which is correlated with the development of castration 
resistance [101, 102]. Simultaneous activation of the AKT/mTOR and MAPK signalling 
pathways also contributes to cancer progression, while inhibition of these pathways results in 
an inhibition of castration resistance in a transgenic animal model [103]. Furthermore, 
PI3K/Akt/mTOR-mediated signalling plays a role in resistance to chemotherapy and 
radiation involving EpCAM [104]. Inside-out activation of β1 integrins by talin1 promotes 
prostate cancer bone metastasis using an in vivo metastasis assay, which is abrogated by 
silencing of the involved talin1 phosphorylation site [105]. A molecular signature based on 
tissue-specific 3D architecture gene expression has been developed to predict diagnosis and 
therapy outcome. Among others, PDCD4 and KLF6 were less prominent in poorly 
differentiated tissues and can be used as prognostic markers in prostate cancer [106]. Most 
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importantly, the molecular bidirectional interplay between tumour cells and osteoblasts 
enhances skeletal metastasis in castration-resistant prostate cancer [107]. 
 
4. Recapitulation of the tumour’s 3D extracellular microenvironment 
Advances in tissue engineering have produced a versatile tool box to design tissue-like 
microenvironments representing specific aspects of the human disease. Bioengineered 
platforms allow a 3D matrix or tissue reconstruction within scaffold-based and organotypic 
cultures and animal models [8]. Awareness of this third dimension has risen dramatically 
over the last decade which has led to a plethora of physiologically relevant 3D cell culture 
technologies to study the biological, mechanical and chemical interplay between cells and 
their natural ECM [9]. The continuous improvement of biomaterial and scaffold design, 
modification and fabrication and the cellular analytical methodologies of 3D cell culture 
matrices have fostered tissue engineering for clinical applications [108]. Interdisciplinary 
approaches aligning tissue engineering with cell biology and medical research contributed to 
tumour-engineered microenvironments to decipher cancer development, progression and 
responses to current treatment regimes and to screen novel anti-metastatic therapeutics [109-
111]. 
 
4.1. Cell-derived matrices 
A tissue-like 3D architecture and composition can be produced by cell-secreted matrices. 
Cell-derived matrices are grown to a thin, microscopy-compatible thickness, and hence 
permit high-resolution imaging in a 3D context [112]. These experimental ECM models, 
grown by different cell types (e.g. mesenchymal cells, fibroblasts), harbour a complexity and 
diversity in their molecular and structural organization to represent the wide range of in vivo 
matrices [113, 114]. As such, a bone marrow-derived ECM was used as an engineered bone 
marrow tissue model of metastasis of prostate cancer cells, thereby regulating factors, such as 
androgen-independent growth and survival, cell phenotype, adhesion and chemoresistance to 
docetaxel, that promote cancer progression [115]. 
Our group established a mineralised human primary osteoblast-derived bone matrix to 
investigate molecular processes implicated in prostatic bone metastasis of LNCaP and PC-3 
cells. This cell-derived matrix has shown high reliability and displays biomimetic properties 
similar to those of native bone. Within this bone-like microenvironment, prostate cancer cells 
displayed morphological plasticity and altered hormonal and proteolytic responses that were 
not seen in traditional cell monolayer cultures. Hence, this decellularised matrix demonstrates 
a robust model system to mimic key features of prostate cancer bone metastases and tumour-
bone interactions [116]. This engineered bone-like matrix can also be used to delineate the 
molecular mechanisms of colonization of other cancer cell types that metastasise to the 
skeleton, such as breast cancer cells [117]. 
 
4.2. Semi-synthetic and synthetic matrices 
A library of biomaterial-based cell culture models is available to address questions of cell-
cell/cell-matrix/cell-surface receptor interactions, signalling pathways, mechanisms of cell 
motility and migration, mechano-biology and tensional homeostasis in a physiologically 
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relevant, tissue-like context. Cells grown in a 3D context respond differently to growth, 
polarity, apoptotic and proteolytic stimuli [118, 119]. 
The gold standards for 3D cell culture systems are Matrigel, a reconstructed matrix produced 
by Engelbreth-Holm-Swarm mouse sarcoma cells, and other naturally-derived, protein-based 
hydrogels, like collagen-based hydrogels [13, 120, 121]. For example, Matrigel has been used 
for ovarian cancer cell-encapsulating droplet patterning to control cell density, growth 
kinetics, cell-to-cell distance and viability [122], for metabolic profiling of ovarian cancer 
cell responses to chemotherapeutics [123] as well as for prostate cancer biomarker expression 
profiling [124], for prostate cancer-stroma 3D co-cultures [125] and to mimic the prostate 
glandular structure [126]. This basement membrane extract has also been used to carry 
ovarian cancer cells within a bioreactor system that allows constant diffusion of oxygen to 
monitor their morphology and growth under hypoxic conditions [127]. Collagen-based 
hydrogels representing a spatial-mechanical 3D culture model [128] and provide a collagen-
rich sub-mesothelial matrix for ovarian cancer cells [129, 130] and an invasive matrix for 
prostate cancer cells [131]. 
To overcome their drawbacks (e.g. high batch-to-batch heterogeneity, undefined matrix 
composition, restricted modification), engineered semi-synthetic and synthetic biomaterials 
have been applied as 3D culture platforms, creating a link between cell monolayer cultures 
and animal experiments [132-134]. These bioengineered matrices offer a combined 
advantage of having native ECM components and tunable material properties resulting in less 
complexity, high reproducibility and comparability between different studies [135]. Such 
tailored matrices can be used to mimic, for example, the 3D architecture of circulating 
tumour cells in a microfluidic microenvironment, where prostate cancer cells form 
clonogenic 3D spheroids within a synthetic biomimetic hydrogel [136]. 
A variety of different hydrogel-based microenvironments to study ovarian and prostate 
cancer (Table 1) will be discussed in the following sections. 
 
4.2.1. Hyaluronan-based hydrogels 
Hyaluronan (also known as hyaluronic acid or hyaluronate) is an integral ECM component 
connective and epithelial tissues and the local tumour microenvironment contributing to cell 
proliferation and migration as well as inflammatory responses during wound repair. 
Hyaluronan-based hydrogels are also suitable as 3D cancer models as they recreate the 
tumour microenvironment (e.g. bone marrow) and allow malignant invasion and the 
evaluation of chemotherapeutics [137-140]. This biopolymer has been used as synthetic ECM 
to grow subcutaneous and orthotopic tumours using injectable hyaluronan-based hydrogels 
(e.g. into the ovarian capsule) in vivo leading to increased vascularisation, thus representing a 
cancer cell delivery vehicle for animal studies [141, 142]. Hyaluronan-based hydrogel 
invasion assays are well suited for the analysis of hyaluronan-interacting factors (e.g. CD44, 
CD168, hyaluronidase) and invadipodia formed by embedded prostate cancer cells [143]. 
Hyaluronan presents an increased selectivity when used in bio-conjugate drug delivery 
systems as its receptors (e.g. CD44, RHAMM) are over-expressed in ovarian cancers and 
mediate intracellular drug release. As such, the conjugation of paclitaxel with hyaluronan has 
shown greater efficacy and less host toxicity upon intraperitoneal treatment of ovarian cancer 
xenografts compared to paclitaxel alone [144]. 
10 
 
4.2.2. Alginate-based hydrogels 
Alginate represents a biocompatible and physico-chemically stable biopolymer that allows in 
contrast to naturally-derived ECM systems (e.g. Matrigel, collagen) the study of cancer cell 
signalling, for example, upon integrin engagement due to incorporation of integrin cell 
binding motifs [145]. Alginate-based hydrogels have been used as 3D organoid cultures to 
provide a scaffold on which cells from ovarian and oviductal tissues can grow and to study 
the origin of ovarian cancer and carcinogenic transformation [146]. 
 
4.2.3. Gelatine methacrylamide (GelMA)-based hydrogels 
The semi-synthetic origin of GelMA-based hydrogels combines the features of naturally-
derived matrices, integrin cell binding motifs and protease cleavage sites, with high stability 
and reproducibly tailorable characteristics, thereby allowing binding to cell adhesion 
receptors and degradation by cell-secreted proteases [147]. GelMA-based hydrogels are 
composed of gelatine, mostly denatured collagen type-I, and offer a 3D cell culture system 
for cancer cells as demonstrated by our group [18] and others [148]. Our group designed a 
quality control and validation protocol to measure the physical and diffusion properties of 
GelMA-based hydrogels performing undefined compression tests and fluorescence recovery 
after photobleaching (FRAP) and demonstrated their application as spheroid carriers within 
an ovarian cancer animal model, thereby promoting local tumour growth and metastatic 
spread as observed in patients with advanced disease [18]. 
 
4.2.4. Polyethylene glycol (PEG)-based hydrogels 
Our group designed a synthetic PEG-based hydrogel model that possesses integrin cell 
binding and protease cleavage motifs to decipher cell-ECM interactions of cancer cells. OV-
MZ-6 and SKOV-3 ovarian cancer cells formed multicellular spheroids in this 3D culture 
model that were representative of metastatic outgrowth within the peritoneal cavity as seen in 
patients with advanced disease [15]. Our group also used this bioengineered ovarian cancer 
spheroid model to assess protease- and integrin-associated functions. Within this 3D system, 
KLK4, KLK5, KLK6 and KLK7 (KLK4-7)-cotransfected ovarian cancer cells formed larger 
spheroids and proliferated more compared to vector controls, particularly upon integrin 
engagement, which was reduced upon integrin inhibition [16]. Moreover, the same 
biomimetic hydrogel model was employed to mimic the prostatic gland microenvironment by 
encapsulation of LNCaP prostate cancer cells. Prostate cancer cells showed morphological 
plasticity and altered their androgenic response compared to traditional cell monolayer 
cultures, implying the presence of tumour-ECM interactions [20]. 
 
5. Engineering the tumour’s cellular niche 
Complex interactions between the tumour and their surrounding host cells, or niche, are 
crucial for carcinogenesis, whereby tumour cells (the 'seed') home to specific organs (the 
'soil'); hence, metastases only occur when the 'seed'/tumour cells and 'soil'/stroma are 
compatible [149-152]. The understanding of the role of the microenvironment in tumour 
biology has recently started to shift since proof has emerged that there is a functional link 
between tumour cells and their surrounding cells and tissues, regulating malignant processes 
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[153, 154]. This dynamic reciprocal tissue network includes intercellular (e.g. cell-cell 
contacts, ECM, chemokines, cytokines, growth factors, proteases) and intracellular (e.g. cell 
surface receptors, kinases, genomic instability) elements [155, 156]. Findings from cell 
culture systems are not as powerful in validating a drug target as animal models are, but they 
do indicate the potential effects of therapeutics. However, experimental confirmation can be 
problematic if the function of a protein in a pathway requires other proteins or cofactors that 
are not present in cell culture approaches using one cell type, such as co-factors or substrates 
produced by different cell types [157]. Hence, a variety of different engineered co-culture 
approaches for ovarian (Table 2) and prostate (Table 3) cancer with stromal-derived cells 
have been used as both tumour entities are a mixture of epithelial, stromal, immune and 
endothelial cells [158, 159]. 
Host and stromal factors, such as ECM components, stromal-derived and inflammatory cells 
and macrophages, in the tumour microenvironment are equally important to early and late 
events in carcinogenesis [74, 160]. Mesothelial cells secrete growth factors (e.g. VEGF, 
FGF2, TGF-β), chemokines (e.g. CXCL4, CXCL6, CXCL8) and cytokines (e.g. IL-6) that 
support the homing of cancer cells to the peritoneal lining. Proteases (e.g. matrix 
metalloproteinase (MMP) 2, MMP9, MMP13, MT1-MMP), present in the tumour fluid 
(ascites), enhance the release of soluble factors from both cancer and mesothelial cells, 
further promoting interactions between both cell types that facilitate the implantation of 
cancer cells onto the peritoneal stroma [161-163]. 
Depending on extracellular stimuli and the interaction with ECM ligands, integrins enhance 
cell survival through several mechanisms, including the activation of signalling pathways 
upon crosstalk with other cell surface receptors (e.g. VEGFR-2), to promote angiogenesis 
[164, 165]. Tumour angiogenesis leads to the formation of blood vessels in a tumour, which 
in turn support cancer cell survival, local tumour growth and the development of distant 
metastasis. Various angiogenesis inhibitors have been approved for anti-cancer treatment as 
single agents or in combination with chemotherapy [166-168]. 
Tumours are organs, and they constantly evolve as they encounter different 
microenvironments [153]. Combinatorial approaches of therapeutics targeting specific factors 
will be required not only to inhibit tumour cell function but also to restore the stromal niche. 
The cytokine network (e.g. CXCR4, CXCL12, TNF-α, IL-6), particularly in the advanced 
disease, is activated and mediates peritoneal tumour spread [169]. As such, IL-6 has tumour-
promoting functions on both tumour and stromal cells. There is preclinical evidence that this 
cytokine enhances ovarian cancer cell survival and mediates treatment resistance due to its 
angiogenic properties. In patients with advanced ovarian cancer, high IL-6 levels correlate 
with poor prognosis [170]. Given its inflammatory role as part of the tumour-stroma niche 
[171], IL-6 antagonising agents are suitable for combinatorial therapy regimes [172]. 
 
5.1. 3D ovarian cancer co-cultures 
Abnormal extracellular factors can enforce cancerous growth; in fact, inflammatory signals 
associated with wound healing promote the development of epithelial tumours [155]. 
Tumours activate parts of the normal wound healing cascades, such as the formation of a 
fibrin clot and the release of growth factors and proteases [173-175]. Hence, our group 
employs a bioengineered microenvironment that is based on a cross-linking reaction that 
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occurs during the fibrin clot formation in wound healing in order to provide the tumour’s 
cellular niche [15]. An integrated 3D co-culture model of ovarian cancer spheroids with 
mesothelial cells was developed to reflect the tumour-stroma niche of the advanced disease. 
In patients, ovarian cancer cells form multicellular spheroids that accumulate in the tumour 
fluid (ascites), grow anchorage-independently and adhere to the stromal layer. To replicate 
this interaction, spheroids were grown within PEG-based hydrogels that comprise ECM 
features due to incorporation of protease cleavage sites and integrin cell binding motifs. 
These were layered onto electrospun-fabricated meshes that allow adhesion of mesothelial 
cells, representing the abdominal lining [176]. Initial high-throughput gene expression 
analyses and signalling profiling show that cancer spheroid growth is enhanced, and that 
genes regulating cell cycle and growth are increased in 3D co-cultures, thus highlighting the 
importance of the tumour-stroma network in disease progression (our unpublished data). 
Another co-culture approach includes the seeding of ovarian cancer spheroids onto 
mesothelial cell monolayers to demonstrate the clearance of mesothelial cells from beneath 
the cancer cells, which is indicative of what is seen in patients with ovarian tumours. This 
spheroid-mesothelium crosstalk occurs through integrin- and talin-dependent activation of 
myosin and contractile forces that are generated by spreading cancer cells [177]. 
As ovarian tumours predominantly metastasise to intra-abdominal organs like the omentum, 
ovarian cancer cells have been co-cultured with adipocytes. Indeed, adipocytes mediate 
tumour growth and facilitate intra-abdominal spread due to the enrichment of fatty acids, 
indicating their contribution to the tumour-stroma network [178]. A complex organotypic 3D 
co-culture model harbouring multiple cell types and a cell-secreted ECM has been developed 
to mimic the early steps of ovarian cancer metastasis within the peritoneal microenvironment 
[179]. Through the analyses of ovarian cancer cells cultured on top of a mesothelial layer, 
which is replicated by primary mesothelial cells seeded on top of primary peritoneal 
fibroblasts that have been mixed with collagen type-I, factors mediating cancer cell adhesion 
and invasion (e.g. fibronectin, vitronectin, different collagens and laminins) have been 
identified [180]. A different 3D co-culture approach utilised mesenchymal stem cell-rich 
amniotic membrane scaffolds that were co-cultured with ovarian cancer cells, mimicking 
early cancer cell migration and infiltration into the sub-mesothelial layer accompanied by 
increased IL-6 levels [181]. 
 
5.2. 3D prostate cancer co-cultures 
The rationale for 3D co-culture models for prostate cancer progression and metastasis to the 
bone using different non-engineered approaches like rotary wall vessel modules has been 
reviewed elsewhere [182]. As disseminated prostate cancer cells have a high affinity to 
skeletal bone, co-cultures of cancer cells with osteoblasts, endothelial and immune cells allow 
signal transduction (e.g. TGF-β/BMP, Wnt signalling) and interaction with tumour-secreted 
proteins (e.g. endothelin-1, ephrins, IL-6, RANKL) and growth factors (e.g. FGF-2, VEGF, 
PDGF) occurring during bone remodelling [183]. RANKL can promote prostate cancer 
metastatic colonisation through autocrine and paracrine RANK-mediated signalling. 
Interestingly, the RANKL-RANK network is associated with an invasive phenotype present 
upon disease progression or therapeutic intervention [184]. 
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A 3D tumour growth assay using co-cultures of PC-3M prostate cancer cells and human 
mesenchymal stem cells was developed, using a commercially-available basal membrane 
extract, to mimic the prostatic niche and to quantitatively screen responses to anti-cancer 
compounds. This high-throughput approach is based on automated microscopy and image 
analyses, applicable to other prostate cancer cells (e.g. LNCaP, DU-145) and suited for large-
scale drug discovery [185]. Another 3D cancer-bone metastasis approach utilised free-
floating murine calvarial bone organs that were co-cultured with prostate cancer cells in a 
roller tube system. Bone formation or resorption was correlated with the metastatic behaviour 
of the prostate cancer cells, demonstrating that the metastatic PC-3 cells induced osteoblastic 
activity and new bone formation, whereas the less aggressive LNCaP cells showed no bone 
resorption and only limited bone formation, accompanied by changes in the gene expression 
pattern (e.g. cysteine proteases, IL-6) [186]. 
Our group designed a tissue-engineered 3D co-culture model of human primary osteoblasts 
with prostate cancer cells employing a cell sheet-based technique. Osteoblast-derived sheets 
are wrapped around a polycaprolcatone-tricalcium phosphate scaffold to fabricate a tissue-
engineered bone construct which is seeded with LNCaP or PC-3 prostate cancer cells to 
mimic osteoblastic and osteolytic responses occurring during bone metastasis. Proteolytic and 
hormonal interactions between both cell types underscored the physiological relevance of this 
engineered bone-like microenvironment [19]. This bone-like microenvironment promoted 
osteomimicry and altered levels of androgen-responsive genes in LNCaP cells under 
androgen-deprived conditions [22]. 
Another 3D co-culture approach utilises BPH-1 non-tumourigenic prostate epithelial cells 
seeded on top of human primary prostate stromal cells (e.g. normal prostate and cancer-
associated fibroblasts) which have been pre-cultured onto coverslips for optimal ECM 
production. This cellularised co-culture leads to phenotypical plasticity and directed 
migration of the non-tumourigenic prostate epithelial cells induced by cancer-associated 
fibroblasts, suggesting a more invasive phenotype. This engineered ECM-like 
microenvironment allows the quantitative assessment of the tumourigenic potential of cancer-
associated fibroblasts [12]. 
A 3D double layered microsphere model was designed to elucidate paracrine interactions 
occurring within the tumour-stroma network. Alginate hydrogel microspheres were generated 
by co-culturing prostate cancer cells (e.g. C4-2) with normal prostate stromal cells (e.g. 
WPMY-1) that were viable for over a month independent of cell type layer combination as 
measured by levels of a soluble E-cadherin fragment, indicative of the secretory function 
[187]. A 3D co-culture approach, which recapitulated the metastatic tumour 
microenvironment by employing 3D collagen-encapsulated lung fibroblasts (e.g. MRC-5) or 
pre-osteoblast-like cells (e.g. MC3T3-E1) layered with prostate cancer cells (e.g. PC-3), 
demonstrated that α3β1 integrin is crucial for tumour-stroma interactions to suppress cancer 
cell growth [188]. A 3D model of tumour-driven angiogenesis was developed to study the 
effects of angiogenic factors produced by prostate cancer spheroids (e.g. LNCaP), grown 
within a basement membrane extract, on arterial explants from human umbilical cords. These 
co-cultures increased angiogenic outgrowth and were less responsive to the anti-angiogenic 
drug Sunitinib [189]. To model the physical interaction of prostate cancer cells (e.g. LNCaP) 
with immune cells in vitro, 3D porous chitosan-alginate scaffolds were seeded with cancer 
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cells and co-cultured with human peripheral blood lymphocytes. The lymphocyte population 
(e.g. T cells, B cells, natural killer cells) homed to the cancer spheroids, thus representing a 
physiological and high throughput tool to assess the efficacy of immunotherapeutics [190]. 
 
5.3. Genetic implications of engineered co-cultures 
Genetic polymorphisms, of which single nucleotide polymorphisms (SNPs) are the main type 
of these sequence variations, have been implicated in ovarian and prostate cancer, for 
example in the human KLK genes [191, 192]. The KLK locus harbours the largest cluster (15) 
of homologous protease genes [193]. SNPs in the KLK genes (e.g. KLK3, KLK15) have been 
linked to a poor ovarian cancer survival [194, 195], while other KLK-related SNPs (e.g. 
KLK4, KLK14, KLK15) have been associated with risk and aggressiveness prostate cancer 
[196-198]. Some of the identified SNPs in the KLK locus (e.g. KLK2, KLK3, KLK15) are 
predicted to alter miRNA binding sites, short non-protein-coding RNA molecules that 
deregulate gene expression by sequence-specific binding to mRNA, and thus, potentially 
interfere with miRNA function [191]. Such miRNAs represent an important control 
mechanism of KLK expression at the post-transcriptional level as a single miRNA can target 
multiple KLKs [199]. Genome-wide miRNA profiling has linked their deregulation to 
ovarian cancer pathogenesis, and their signatures can potentially be used as diagnostic and 
prognostic tools for this disease [200]. Interestingly, miRNAs can modulate the sensitivity to 
PARP inhibitors and can potentially serve as biomarkers to identify a subset of ovarian 
cancer patients that benefit from a therapy with PARP inhibitors [201]. 
In our integrated 3D ovarian cancer co-culture model (our unpublished data), some of the 
miRNA that are reported to be altered in cancer, including ovarian [202-204] and prostate 
cancer [205-207], and affect tumour development, progression and angiogenesis [208]. The 
gain or loss of a cell type-specific miRNA network can act as an oncogene and/or tumour 
suppressor [192]. Interestingly, alterations in miRNAs expressed by the stroma (mesothelial) 
cells have been shown to play a role in the tumour microenvironment underlining their 
tumour growth-promoting and/or growth-suppressing functions [209]. The ovarian tumour 
microenvironment can re-program normal fibroblasts into cancer-associated fibroblasts due 
to changes in the miRNA expression in the quiescent fibroblasts, thereby promoting the up-
regulation of chemokines (e.g. CCL5) that drive invasion and metastasis [210]. Strikingly, a 
novel targeted approach combining an EphA2, a receptor tyrosine kinase that is linked to 
poor outcome in ovarian and prostate cancer, tumour-suppressing miRNA and RNA 
interference (e.g. small interfering RNA) represents an innovative technique for a dual gene 
silencing therapy for cancer with high efficacy [211]. 
 
6. Cancer-associated protease function in 3D microenvironments 
Susceptibility to enzymatic degradation allows for cell-mediated remodelling and migration 
within cell-laden biomaterials that are crucial for normal developmental and homeostatic 
processes as well as pathological processes occurring during wound repair and disease 
progression. Proteolytic systems, such as MMPs, cysteine and serine proteases, have been 
linked to ovarian [212] and prostate [213] cancer progression as they are frequently up-
regulated in malignant tissues and modulate ECM components, process secreted molecules 
and cell surface receptors, alter signalling functions and cellular behaviour, thereby 
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facilitating carcinogenesis [157, 214, 215]. However, several MMPs and KLKs harbour 
tumour-protective or dual cancer-modulating properties in different stages of disease 
progression by numerous distinct pathways [214, 216-219]. To decipher KLK-mediated 
proteolysis of putative substrates in ovarian and prostate cancer, our group is using mass 
spectrometry-based proteomic approaches in a biologically-mimetic context, and is currently 
validating the functional consequences of the KLK degradome in various engineered 3D 
models [220]. To detect cell-dependent proteolytic activity locally within 3D matrices, 
various fluorescent substrates, which cause a dramatic increase in fluorescent intensity upon 
proteolytic degradation, have been used [221]. 
Although cell-mediated proteolytic activity is detectable in different 3D microenvironments, 
there is also evidence of a non-proteolytic cell migration through 3D matrices [112]. 
Migration through 3D matrices (e.g. collagen matrices) occurs in a multi-step mode with 
alternating stationary and migratory phases [222]. Cancer cells maintain their migratory 
ability after broad-spectrum inhibition of cell-dependent proteolysis (e.g. MMPs, cysteine 
and serine proteases) exhibiting a non-proteolytic amoeboid migration type. The transition of 
a mesenchymal to an amoeboid movement is accompanied by morphodynamic (e.g. 
constriction ring, diffuse actin distribution) and molecular changes (e.g. integrin and MT1-
MMP clustering) [223]. When pericellular proteolysis is blocked by a cocktail of inhibitors, 
some cancer cells exhibit a rounded phenotype and require Rho-ROCK signalling, ultimately 
increasing the invasive behaviour of these cells [224]. However, the extent of proteolysis 
depends on the specific cell type, combination of protease inhibitors, type and composition of 
the 3D matrix and architecture [112, 222]. The migratory behaviour depends on the matrix 
stiffness; while low matrix stiffness fosters a non-proteolytic 3D migration mode, a higher 
stiffness allows proteolytic migration in artificial ECMs [225]. 
A variety of different approaches to measure cancer-associated proteolytic activity in 3D and 
live organisms (Table 4) will be discussed in the following sections. 
 
6.1. Proteolytic factors in the tumour’s cellular niche 
The tumour-promoting functions of proteases are embedded within a multidirectional 
interactive network to modulate angiogenesis, cancer cell invasion, ECM composition and 
signalling cascades in the tumour microenvironment. Hence, it needs to be taken into account 
that proteases are not only expressed by cancer cells but also stromal-derived cells which 
increases the diversity of the proteolytic machinery because proteases usually not expressed 
by cancer cells are now present [226]. Most importantly, tumour-stroma interactions can 
modulate the expression levels of proteases [227]. Proteases are not only produced by 
invasive cancer cells but also by non-malignant cells of the tumour microenvironment (e.g. 
MMPs, cysteine cathepsins, serine proteases) facilitating cancer cell invasion, intravasation 
and dissemination to distant organs. Individual proteases cleave cell-adhesion molecules (e.g. 
E-cadherin) leading to the disruption of cell-cell contacts, degrade ECM and basement matrix 
proteins allowing invasive cancer cells to migrate into the surrounding tissues and process 
pro-domains subsequently activating growth factors, cytokines and signalling cascades [175]. 
For example, the expression of MT1-MMP within the tumour microenvironment has been 
linked to its proteolytic activity and has led to the design of a tumour-targeted prodrug as a 
therapeutic strategy for solid tumours like prostate cancer [228]. Altered tumour 
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microenvironment dynamics influence the behaviour of both cancer and stromal, endothelial 
and immune cells, thereby actively contributing to cancer cell proliferation and survival 
[229]. 
The degradation of quenched-fluorescent (DQ) collagen type-I/IV by various proteases can 
be imaged and quantified by confocal microscopy in 3D cultures of prostate cancer cells 
[230] and 3D organotypic cultures using multiple cell types [231]. Recently, quantitative 
image analyses has entered the fourth dimension, namely time, and cancer cell-associated 
proteolysis can be measured in 3D co-cultures of cancer spheroids with stromal-derived 




Biodegradability of synthetic hydrogels is engineered by incorporation of peptides containing 
specific sequences sensitive to cleavage by MMPs [233]. Fluorogenic substrates, such as 
fluorophores-labelled native ECM proteins, have been used to visualise protease activity, 
whereby cleavage of the fluorescent protein by cell-secreted MMPs separates the 
fluorophores and releases a fluorescence signal [221, 231]. To overcome the high background 
signals of these fluorescently-labelled proteins, fluorogenic peptide substrates have been 
incorporated into synthetic hydrogels [234, 235], whereby close proximity of two 
fluorophores on the non-cleaved peptide results in quenching, and cleavage by MMPs 
separates the fluorophores generating a fluorescence signal that corresponds to MMP activity 
and collagen type-I matrix degradation by migrating prostate cancer cells [227]. Hence, 
fluorogenic MMP-sensitive peptide substrates have been used to quantitatively monitor the 
spatial distribution of cell-mediated MMP activity by real-time measurements in 3D cell 
cultures [236]. Fluorescein (DQ)-conjugated collagen becomes fluorescent when 
fluorophores are separated due to pericellular proteolysis occurring during cancer cell 
invasion of a 3D nylon mesh-supported gelatine matrix [237]. 
With the help of sophisticated cancer cell-ECM interfaces a variety of different proteolytic 
structures have been identified to contribute to pericellular ECM degradation and remodelling 
during proteolytic cancer cell invasion through 3D fibrillar fibrin or collagen matrices [238]. 
 
6.3. Cysteine proteases 
Molecular imaging technologies comprise, for example, fluorescently-based probes that 
become activated by cancer-associated proteases (e.g. cathepsins) in conjunction with 3D 
optical imaging to detect very small tumours and response to therapy in vivo [239]. Magnetic 
resonance imaging coupled with 3D fluorescence molecular tomography was used for in vivo 
fluorescent imaging of ovarian tumours and their response to therapy. Upon cathepsin 
activity a fluorescent signal was detectable and positively correlated with tumour size. In the 
same study, fluorescent molecular imaging probes, relevant to ovarian cancer, were also used 
to detect MMP activity and αvβ3 integrin binding but resulted in a lower signal compared to 
that for the cathepsin activity [240]. Thus, probe activation and retention in tumours are 
directly indicative of the activity of protease expressed by cancer cells. 
Activity-based probes are highly selective in detecting catalytically active forms of proteases 
within living cells or organisms using modern imaging technologies, thereby also visualising 
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the localisation and distribution of active proteases [241]. Fluorescently-quenched activity-
based probes have been used to monitor the activity of multiple cathepsins in 3D cultures in 
vitro and tumour microenvironments in vivo [242, 243]. Computational modelling predicted 
the interactive proteolysis of cysteine cathepsins in the local microenvironment, allowing the 
separation of individual cathepsin activity. Fluorogenic substrate assays revealed that 
cathepsin S degrades cathepsin K, and consequently results in reduced ECM remodelling, 
including collagen type-I degradation [244]. An interesting approach utilising a split luciferin 
ligation reaction has determined the activity of caspase 3 and caspase 7 in live ovarian 
tumour-bearing animals by bioluminescence imaging upon drug-induced apoptosis [245]. 
 
6.4. Serine proteases 
The enzymatic activity of the KLK serine proteases can be evaluated by the design of small 
molecule inhibitors that selectively target the active form of the protease to prevent the 
tumourigenic behaviour [246]. In a 3D suspension culture that represents the ascites 
microenvironment, the selective active site KLK4 sunflower trypsin inhibitor reduced the 
multicellular aggregation of ovarian cancer cells and increased their sensitivity to paclitaxel, 
thereby providing a potential combination strategy for anti-metastatic therapies [247]. 
 
7. Drug screening in 3D microenvironments 
For preclinical screening of drug efficacy and the assessment of drug responsiveness the cell 
line and culture models used need to be carefully chosen to reflect maximal molecular 
similarity to tumour tissue of a distinct subtype. Cell line models that are genetically 
characterised can guide the selection of cancer patients, depending on genomic heterogeneity, 
suitable for clinical trials specifically designed for a particular histological subtype, to yield 
higher response rates [248, 249]. As the minority of new drugs show anti-cancer activity in 
clinical trials, there is an urgent need for pre-clinical drug screening models that better mimic 
the complex in vivo architecture of primary tumours. High-throughput technologies provide 
the opportunity for genomic-based drug discovery studies, thereby allowing systems-level 
analyses of cancer cell behaviour in a physiological 3D microenvironment [250, 251]. 
The chemo-response of epithelial ovarian cancer, the most common subtype of ovarian 
cancer, was evaluated using a 3D microenvironment allowing multicellular aggregation of the 
cancer cells. It was reported by us [13, 15] and others [252] that cells grown in 3D were more 
chemo-resistant compared to traditional monolayer (2D) cultures, thus implying a critical 
impact on drug testing approaches, drug design strategies and mechanism underlying drug-
resistance. In a comprehensive study, 31 epithelial ovarian cancer cell lines were 
characterised for their chemosensitivity towards cisplatin (0.1 mg/ml) and paclitaxel (100 
nM) when grown in 2D and 3D cultures. The authors showed that 3D-cultured cells had a 
significant increase in survival to both chemotherapeutics, including a 30% increase upon 
cisplatin treatment, compared to 2D cultures. Additionally, the 3D microenvironment 
reflected the characteristics of primary ovarian cancer cells in vivo and their histological 
classification, such as reduced proliferation rates and enhanced E-cadherin, cytokeratin, 
PAX8 and CA125 expression. Hence, this high-throughput approach is suitable for drug 
discovery and preclinical drug development [253]. 
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Our group developed a hydrogel microwell array platform to analyse the survival of ovarian 
cancer cell aggregates in response to paclitaxel (100 nM) using a high-throughput mode. This 
technology allows the precise control of the aggregate size layered on top of hydrogel 
microwell arrays and to assess the efficacy of drug treatment dependent on aggregate size. 
Within this hydrogel-based model, the expression of β1 integrin was increased upon 
paclitaxel treatment, underscoring the critical function of this integrin in paclitaxel-related 
resistance. The administration of paclitaxel reduced aggregate area but not numbers. KLK4-
7-expressing ovarian cancer cells showed a higher ability to aggregate and to survive 
independent of paclitaxel in all microwell sizes tested compared to vector controls [17, 254]. 
These findings imply that biomedical engineering technologies will advance the current 
cancer cell modelling and ultimately lead to novel anti-metastatic therapeutic interventions 
that translate into improved clinical strategies and prolonged patient survival [111]. 
A high-throughput 3D invasion assay has been used to screen the response of invasive cancer 
cells, including prostate cancer cells, to various anti-invasive and cytotoxic drugs. Cancer 
cells were encapsulated within collagen I-based hydrogels to allow spheroid formation and 
drug treatment to develop a standardisation and automated quantification protocol. Co-
staining with nuclear (e.g. Hoechst33342) and apoptotic (e.g. propidium iodide) markers 
helped to simultaneously evaluate the anti-invasive and/or cytotoxic effect of a specific 
compound [255]. This study shows that high-throughput 3D platforms represent a precise, 
reproducible, quantitative and phenotypic screening tool for large scale anti-cancer drug 
discovery. 
 
8. Engineered cancer animal models 
The determinants and key mechanisms of cancer progression have not yet been fully 
delineated, mainly due to the lack of reproducible animal models that represent the 
biological, genetic and clinical features seen in patients. While transgenic and syngenic 
animal models can answer specific questions about metastatic processes, they fail to predict 
drug efficacy against a panel of human tumours with a given histology. Furthermore, the time 
it takes to develop tumours in these models is variable, and usually experiments are limited to 
long-term studies [256, 257]. For example, in ovarian cancer, intraperitoneal injections of 
single cell suspension of cancer cells derived from a primary tumour tissue do not replicate 
the early metastatic processes. Orthotopic ovarian xenografts mimic more closely the 
dissemination of cancer cells from the primary tumour, and therefore, reflect the metastatic 
phenotype [158]. In prostate cancer, transgenic and syngenic models do not allow the 
replication of the advanced disease as they usually lack a robust skeletal metastatic phenotype 
[258]. 
Therefore, most insights about the progression of ovarian and prostate cancers are still 
derived from xenograft models [21, 159, 259, 260]. Xenograft injections of human cancer 
cells into murine tissues have been routinely used as in vivo models to study various aspects 
of human tumour pathogenesis and responsiveness towards therapeutics. However, there are 
fundamental differences between both species in terms of anatomy, lifespan, cancer 
susceptibility and cytogenetic alterations. Humanising the host organism with human 
stromal-derived cells or factors prior to engrafting of human cancer cells substantially 
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improves the value of xenograft models to fully mimic the relationship between the human 
tumour cells and the complex human microenvironment [261]. 
Within this context, tissue engineering approaches and material sciences, which originally 
had been focused on repair and reconstitution of damaged tissue structure and function [3, 
262], can offer ‘cancer research the third dimension’ [8]. It is apparent that these powerful 
and modular tools are not only used to resemble the physiology of healthy tissues but also to 
replicate the physical and biochemical microenvironment of human primary and secondary 
tumours [21]. To replicate the complex metastatic processes, intratumoural and paracrine 
signalling events of cancer progression, the pre-metastatic sites, including its various cell 
types (e.g. mesothelial cells, osteoblasts, fibroblasts), need to be considered and engineered. 
The metastatic microenvironment of ovarian cancer is restricted to the organs (e.g. omentum, 
liver, intestine, kidney, spleen) of the peritoneal cavity, while prostate cancer metastasises 
primarily to the skeletal bone causing osteoblastic, osteolytic or mixed lesions [175]. 
 
8.1. Ovarian Cancer – Engineered mesothelium 
The only non-human animal model that spontaneously develops ovarian cancer with a high 
incidence is the laying hen, with evidence of abdominal metastasis and accumulation of 
tumour fluid (ascites) that is similar to that found in patients with late stage disease. 
However, the abundance of the histological subtypes and hormones differs between birds and 
humans [263]. Transgenic engineering is very limited as it can only be performed on chicken 
embryos using, for example, gelatine-based nanoparticles [264]. In order to decipher the 
genetic and molecular alterations occurring during ovarian cancer progression, D. 
melanogaster has been used as a simple model organism as border cells share some features 
(e.g. migratory behaviour) with ovarian cancer cells [265]. The majority of ovarian cancer 
animal models are based on xenografting of human ovarian cancer cells into immunologically 
compromised mice [266]. But these xenograft models have drawbacks, including the 
incomplete replication of tumour-stroma interactions and the inability to recapitulate the early 
stages of tumour development [267]. Genetically modified animal models of ovarian cancer 
overcome some disadvantages of these xenograft models, as tumours arise in the appropriate 
location and mimic the initiation and clinical route of metastasis seen in patients [71, 268, 
269]. 
Our group established a xenograft model of ovarian cancer growth using cancer cells that 
have been modified to allow bioluminescence imaging to non-invasively monitor tumour 
growth in living animals over time (Figure 2). Ovarian cancer spheroids were grown for two 
weeks within biomimetic PEG-based hydrogels in vitro prior to implantation into NOD/SCID 
mice. During surgical procedure, the reproductive tract is exposed, revealing the ovaries 
between the oviduct and the surrounding fat pad. A spheroid-containing hydrogel is placed in 
direct contact to the ovary (one implant on the left ovary, one implant on the right ovary) and 
the adjacent fat tissue which ensures a constant and reproductive growth rate of the cancer 
spheroids. The structural integrity of the bursa is maintained, and a tumour mass is formed on 
the ovaries (Figure 3). The implants are eventually surrounded by peritoneal fluid that 
enables the ovarian cancer cells to escape their engineered microenvironment and attach 
preferentially to the mesothelium of the peritoneal cavity, resulting in the typical pattern of 
metastatic lesions seen in the clinical sequence of metastases, in loco-regional lymph nodes, 
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the omentum, liver and sigmoid colon (Figure 4). Our spheroid-based animal model is more 
physiological and reflects more closely the disease progression seen in patients as tumour 
growth is observed over 4-8 weeks using 100 times less cells compared to commonly used 
animal models which administer 10 million cells as single-cell suspension and grow tumours 
over 8-12 weeks. Using this bioengineered intraperitoneal animal model, combined KLK4-7 
expression significantly promoted early-phase tumour growth (after 4 weeks), thus validating 
the in vitro protease-mediated enhancement of spheroid growth in vivo. After 8 weeks, no 
significant differences in tumour weight and volume in both KLK4-7-expressing and KLK4-
7-deficient groups were detected. However, in this late-phase, the number of metastases was 
distinctly enhanced upon the presence of KLK4-7 over-expression in the tumour cells [16]. 
This spheroid-based animal model has already provided new insights into ovarian cancer 
pathogenesis [16] and has proven useful for preclinical testing of novel therapeutics that 
target specifically ovarian cancer cells (e.g. integrin antagonists [18]), stromal-derived 
molecular factors (e.g. IL-6), and signal transduction (e.g. mediated by tyrosine kinases) 
inhibitors [76]. 
Currently, this 3D co-culture model of ovarian cancer spheroids with mesothelial cells is 
validated in vivo using orthotopic implants to enable organotypical interactions between 
human tumour cells and human stroma. Other in vivo human tumour-promoting niche models 
include human embryonic stem cell-derived microenvironments to study the tumourigenic 
heterogeneity among cancer cell subpopulations from ascites-derived ovarian cancer cells in 
order to distinguish cancer cells amenable to anti-cancer therapy screening [270]. 
 
8.2. Prostate Cancer - Engineered Bone 
The xenotransplantation of human prostate cancer cells or tumour tissue into immuno-
compromised murine hosts provides the possibility to simulate early and late stages of the 
human disease. In conventional xenograft models of metastatic prostate cancer, the skeleton 
as the predominant homing site of human cancer cells is of murine origin [271, 272]. As a 
consequence, human prostate cancer cells grow within and interact with the murine bone 
microenvironment. Hence, these models are not suited for the analyses of species-specific 
interactions of human prostate cancer cell osteotropism. To overcome these limitations, a 
humanised approach using subcutaneously xenotransplanted human bone fragments as 
homing sites for inoculated human cancer cells was designed [273-278]. However, these 
attempts to successfully transplant functional human bone into a murine host have failed [21]. 
The transplanted bone does not sufficiently mimic the morphological and functional 
characteristics of vital human bone as it is poorly vascularised and necrotic. Furthermore, the 
implanted bone tissue cannot recapitulate a functional vascular and endosteal niche for 
haematopoietic stem cells which results in the progressive replacement of the haematopoietic 
marrow by fat cells and fibrotic tissue [279-281]. To date, it is known that metastatic cancer 
cells usurp the homing pathways of haematopoietic stem cells to establish footholds in their 
microenvironment [282-284]. Therefore, the establishment of a pre-metastatic haematopoietic 
niche seems to be indispensable for the development of prostate cancer bone metastasis. 
Tissue-engineered humanised bone can overcome the limitations of conventional xenograft 
models of prostate cancer bone metastases by creating bone constructs with vital human bone 
cells and a functional bone marrow compartment. This approach simulates the conditions 
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seen in the clinic more precisely as prostate cancer bone metastases are mainly found in the 
axial skeleton characterised by a high content of proliferative red bone marrow [285]. Several 
heterotopic bone models have been developed that use tissue engineering techniques to 
mimic the physiological conditions of a functionally intact organ bone. Hence, it is possible 
to enhance heterotopic bone formation, increase vascularisation and ultimately create a 
tailored niche for haematopoietic stem or prostate cancer cells. Most models apply cell-
seeded scaffolds based on ceramic materials [286-291], synthetic polymers [292] or scaffolds 
that contain naturally occurring components, such as collagen meshes [288, 293], gelatine 
sponges [294, 295] and cellulose matrices [296]. Others used de-mineralized bone matrices 
[297] or gelatinous protein mixtures, such as Matrigel [298], to induce the formation of new 
bone with haematopoietic marrow. 
Schuster and colleagues [299] were the first to use this approach to study the growth of 
human prostate cancer cells within a humanised tissue-engineered bone construct. 
Hydroxyapatite-coated collagen sponges seeded with human osteoblasts were subcutaneously 
implanted into male SCID mice. After de novo bone formation, PC-3 prostate cancer cells 
were injected into these bone constructs. Histological analyses confirmed tumour masses in 
all transplanted scaffolds. Unfortunately, the viability and composition of the newly formed 
bone was not further analysed [299]. Moreau and colleagues [300] cultured human bone 
marrow-derived stromal cells on silk fibroin sponges that were coupled with BMP-2. After 
bone formation, luciferase-labelled SUM1315 human breast cancer cells were orthotopically 
implanted into the mammary fat pad of female NOD/SCID mice. Metastatic spread was only 
detected to the implanted human bone constructs but not to the murine skeleton. In a later 
study from this group, metastatic spread was also evident in the murine skeleton [301, 302]. 
Therefore, the species-specificity of this approach has still to be proven. 
So far, only these two groups [299, 300] applied tissue-engineered principles to analyse the 
mechanisms of human cancer cell osteotropism within a murine host. However, in these 
models, the bioengineered bone constructs were not sufficiently characterised in terms of 
their bone biology. Histological analyses did not show the morphological characteristics of a 
functional organ bone as the bone marrow spaces were mainly filled with connective tissue 
and not with the typical cellular components of physiological bone marrow. Furthermore, the 
bone matrix was interspersed with the carrier material which interferes with the development 
of a coherent physiological tissue network [300, 302]. Therefore, metastatic lesions occurred 
within a non-physiological, immature bone microenvironment. 
At present, our interdisciplinary group is creating a novel tissue-engineered xenograft model 
of prostate cancer bone metastasis to recapitulate more subtle, species-specific aspects of the 
mutual interaction between human prostate cancer cells and a humanised physiological bone 
microenvironment (Figure 5). Our results show that homing of the human prostate cancer 
cells indeed occurs at a humanised organ bone with a morphologically intact marrow 
compartment [24]. A large amount of human osteocytes and human-derived matrix proteins 
are incorporated in these constructs. In contrast to human bone, these humanised tissue-
engineered bone constructs are reproducible, consistent and not limited in supply [23]. The 
amount and viability of the cells seeded onto the scaffold material can be monitored before 
implantation into the murine host. This approach reproducibly tailors the characteristics of 
the humanised constructs according to the experimental purpose and ensures the quality of 
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the cell-seeded construct prior to implantation [24]. In the future, human haematopoietic 
elements can be introduced into the construct to further increase the value of the model to 
allow interactions between human immune cells and the tumour within the murine host. 
 
9. Mechanical and metastatic properties of cancer cells 
The rapidly increasing research into the dynamic biological and functional characteristics of 
metastatic cells and their heterotypic niche has uncovered a number of new anti-metastatic 
targets to move the field of personalised cancer therapies forward [303]. Consequently, there 
is a constant progress to decipher interactions between biomechanical effects and intracellular 
and intercellular signalling in order to understand cancer growth, its interaction with the 
surrounding stroma, cell invasion and metastasis [304, 305]. The invasive behaviour of 
ovarian cancer cells and spheroids is inversely correlated with their stiffness leading to 
cytoskeletal remodelling and altered adhesion to ECM [306, 307]. A decrease in cell stiffness 
seems to be greater with higher malignant and metastatic potential [307]. However, the 
detailed mechano-biology of ovarian cancer spheroids and tumour tissue has not yet been 
determined. With the exception of Xu and colleagues [306], there is limited information 
regarding the biomechanics of ovarian cancer cells. There are few methods available for 
characterising cell mechanics, and of these, atomic force microscopy offers unique 
advantages over other popular methods to determine cell mechanics in an extremely localised 
area [308]. The cells (e.g. from pleural fluids), harvested for atomic force microscopy nano-
mechanical testing are most commonly cultured in monolayers, but not in spheroids [309]. 
Our unpublished results suggest that cancer spheroids derived from spheroid-based 
xenografts were softer than normal ovarian tissue suggesting that stiffness may be a useful 
indicator to evaluate the aggressive potential of this disease. Interestingly, paclitaxel 
treatment of cancer spheroids and tumour tissues increased the elastic modulus, implying that 
altered biomechanical properties are an indication of therapy responsiveness and anti-
metastatic approaches (Figure 6). The analyses of the nano-mechanical profiles and nano-
structural organisation of the cytoskeleton of ovarian cancer cells have revealed a potential 
chemoresistance-associated mechanism, implying an inter-linkage between actin remodelling 
and drug-induced increase in cell stiffness [310]. 
These mechano-biological data built sub-cellular parameters that can be integrated into 
computational simulation approaches to advance the current knowledge of ovarian cancer 
progression, in particular multicellular cancer spheroids, and treatment [311]. Computational 
modelling is a proven tool to assist and improve in vivo treatment methods and to 
demonstrate the efficacy of various treatment combinations [312]. Our confined compression 
tests showed that normal ovarian tissue was softer than tumour tissue, which has also been 
reported for other epithelial cancers and control tissues [313]. This altered micro-rheology 
can be advantageous during cell invasion at metastatic sites and extra-vasation of the 
vasculature, thereby promoting cancer progression. Indeed, tumour rigidity is a response to 
the increased interstitial tissue pressure and solid stress upon a perturbed vasculature and 
tumour growth [314]. It was shown that interstitial flow-induced forces increased the 
metastatic cell motility, involving integrins, MMPs and CD44, and mechano-transduction 
through hyaluronan and heparan sulphate in a 3D collagen-based hydrogel suspension model 
[315]. 
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Computational modelling has provided insights into the changes of the mechanical 
architecture and cell migration of prostate cancer cells that occur over time in a 3D 
microenvironment [316]. Araujo and colleagues developed an integrated computational 
model to predict the cellular interactions upon treatment of bone metastasis occurring during 
prostate cancer progression to the bone [317]. The interdependence of cell motility on matrix 
stiffness and protease activity was experimentally quantified, indicating that the invasive and 
proteolytic (e.g. MMP2, MMP9) capabilities of cells depend on the rigidity of the 
microenvironment [131]. Mathematical simulation combined with experimental 3D systems 
help to understand the cellular behaviour at a systems-level during cancer progression, 
suggesting that invasive cancer cells more actively remodel the ECM and its dynamics to 
facilitate metastasis [318]. 
The tissue microenvironment and the ECM architecture control the force acting on cancer 
cells, and reciprocally, these cells respond via their mechano-receptors (e.g. integrins) to the 
exogenous forces (e.g. matrix stiffness) by cell-generated forces creating a mechanical 
interdependence [128]. The stiffening of the extracellular microenvironment can predict the 
presence of malignant cells. The rigidity of a tumour is accompanied with an increased 
stiffness of the surrounding stroma and mechano-regulatory events (e.g. Rho-dependent 
cancer cell growth, contractility, integrin clustering) that facilitate an oncogenic phenotype 
[314, 319]. Mechanical tension from the extracellular microenvironment also affects the 
physical properties of the nucleus, thereby regulating gene expression, nuclear rheology and 
cell fate [320]. LaminA was identified as key factor of the tension-mediated transcriptional 
regulation resulting in the tissue-specific activation of mechano-sensitive signalling pathways 
[321]. The emerging challenges in understanding and targeting the complex cell-biological 
and mechano-chemical interactions occurring during tumour metastasis require integrated 
and multi-disciplinary approaches [8, 121, 153, 311, 322]. 
 
10. Conclusion and future directions 
Although several breakthroughs in anti-cancer drug development have been accomplished in 
the last decades, it is estimated that, especially in developing countries, the cancer burden 
will significantly increase in the near future. This is mostly due to the fact that the 
understanding of cancer cell biology and the contribution of the tumour microenvironment to 
disease progression and implicated signalling pathways is still rudimentary. Sensu stricto, 
most conventional cell culture approaches fail to model the tumour’s niche as they usually 
focus on single-scale events in cancer development or progression. However, as highlighted 
in this review, carcinogenesis and metastasis are multi-scale processes including alterations at 
the genetic, molecular, cellular, tissue and organ level which influence each other in a 
reciprocal way. Thinking outside the box and applying tissue engineering principles with a 
multi-disciplinary modus operandi can lead to a better understanding of the individual steps 
promoting carcinogenesis and finally enables the study of cancer in multi-scale and systems-
level platforms according to the principle of ‘the whole being greater than the sum of its 
parts’. 
The contributions of the tumour microenvironment to cancer progression and signal 
transduction are multi-facetted. Engineered tumour models have already provided 
biologically and physiologically relevant insights into the interdependence of carcinogenesis 
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and the surrounding milieu, thereby affecting responses to therapeutics. Tissue engineering 
principles can further be used to develop personalised tumour models that allow for growing 
patient-derived primary cells or tumour tissue within its native microenvironment to develop 
patient-specific, individualised therapeutic strategies. However, tumour engineering will only 
have a lasting impact on the cancer research field if it allows the translation of novel anti-




D.L. and J.A.C. are supported by the Australian Research Council, the Cancer Council 
Queensland and National Health and Medical Research Council of Australia. D.L. was 
awarded a Cells and Tissue Domain Collaborative Research Development grant from the 
Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Australia. B.M.H. is supported by the German Research Foundation (DFG HO 5068/1-1). 
The authors would like to cordially thank Dr Christina Theodoropoulos and Thi-My-Tam 








Figure 1. Tissue engineering provides a platform to study species-specific homing 
mechanisms of human cancer cells. This approach allows testing of drug efficacy against a 
panel of human tumours within an immunocompromised murine host and developing of 
individualised, patient-specific therapeutic strategies. Left panel: Mesenchymal cells are 
obtained from prostate cancer patients, cultured under osteogenic conditions and seeded onto 
composite scaffolds. After implantation, a tissue-engineered humanised organ bone develops 
within the host. Human prostate cancer cells are cultured and inoculated into the animal via 
intracardiac injection or orthotopic implantation into the prostate capsule. Finally, the effects 
of novel therapeutic strategies on the development of bone metastases can be investigated. 
Right panel: Mesothelial cells are obtained from non-cancerous individuals, cultured on an 
electro-spun scaffold and implanted into the animal’s abdominal cavity to mimic the human 
mesothelium as the native soil for metastasizing ovarian cancer. Tumour cells are cultured 
and embedded into a 3D matrix to develop multicellular spheroids. After implantation of 
these constructs into the abdominal cavity, homing of human ovarian cancer cells to the 
humanised mesothelium can be analysed. Finally, the efficacy of novel anti-cancer drugs can 





Figure 2. Xenograft model of intraperitoneal ovarian cancer growth using a 
bioengineered 3D construct. A. Ovarian cancer OV-MZ-6 cell spheroids were grown for 2 
weeks within a bioengineered 3D model prior to implantation into 6 weeks old female 
NOD/SCID mice. An abdominal incision parallel to the longitudinal body axis was made to 
expose the peritoneal cavity and to place the spheroid-containing hydrogel implant adjacent 
to both ovarian fat pads. B. The correct placement of the spheroid-containing implants was 
confirmed via bioluminescence imaging (7.5 mg/ml D-luciferin; Caliper Life Sciences) 
directly after surgery using a live organism imaging system (IVIS® Spectrum 200, Perkin 
Elmer; Living Image® software v.4.3.1). C, D. Intraperitoneal tumours developed over the 
duration of the studies and were visible (about 11mm in diameter) at the time of termination 
after 8 weeks. E. The accumulation of tumour fluid (ascites) within the peritoneal cavity was 
evident (arrows). F. Cancer spheroid implants (red arrow) caused tumour spread throughout 
the abdominal cavity (black arrows). The metastatic distribution pattern observed in the 
intraperitoneal animal model was comparable to the clinical route of metastasis with the 
largest secondary tumour masses seen in the omentum G. Intra-operative situs of a 48 year 
old patient diagnosed with ovarian cancer and peritoneal carcinomatosis showing the typical 
omental cake, an extremely thickened omentum caused by massive tumoural infiltration 
(black arrow; picture was kindly provided by Prof Dr Joerg Pelz, Department of Surgery, 





Figure 3. Immunohistochemical characterisation of ovarian cancer development and 
progression in the bioengineered 3D model. To evaluate the growth of the human cancer 
cells observed in the intraperitoneal ovarian cancer animal model, paraformaldehyde (PFA)-
fixed, paraffin-embedded serial sections (5µm) of spheroid-based xenografts and the 
metastatic lesions were immunohistochemically processed using an EnVision™ Flex, high 
pH detection system (Dako). Antigen retrieval was performed by 95ºC treatment using the 
provided target retrieval solution (high pH) followed by blocking in 2% BSA/PBS. Human-
specific antibodies against the nuclear mitotic apparatus protein 1 (NuMA; 1:100; Epitomics), 
cytokeratin8 (KRT8; #M20; 4 µg/ml; Abcam), a epithelial cancer cell marker, and vimentin 
(Vim; #V9; 1 µg/ml; Abcam), a mesenchymal cancer cell marker, were incubated for one 
hour at room temperature, and their binding visualised using 3,3’-diaminobenzidine as 
chromogen (Dako). Sections were counterstained with Mayer’s hematoxylin and imaged with 
a widefield microscope (LaborLux, Leitz; DXM1200C digital camera, Nikon; ACT-1C 
software v.1.01) with a 10x and 20x air objectives. While no staining of the fallopian tube 
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and the healthy ovary was detected, human-derived malignant growth in the neoplastic ovary 
and lesions in the omentum and mesocolon were evident as indicated by positive staining for 
NuMA, KRT8 and Vim. Scale bars, 1 mm (overview insert in NuMA staining), 200 µm (top 




Figure 4. Ovarian cancer metastasis in the bioengineered 3D model. A. Within the 
intraperitoneal ovarian cancer animal model, widespread abdominal lesions were detected by 
bioluminescent imaging and evident in the liver (B, C, D; arrows), omentum (C, E; arrows) 
and mesothelium of the intestine and colon (F; arrows). F, G. The omental metastatic spread 
was remarkably reduced by treatment with paclitaxel (4 weeks after tumour growth, animals 
were treated with 10 mg/kg paclitaxel twice per week over 4 weeks; arrows). H. 
Immunohistochemical analyses of PFA-fixed, paraffin-embedded metastatic tissues of the 
liver, kidney and spleen indicates a positive staining for the human-specific antibodies 
directed against NuMA, Ki67 (#MIB-1; 1:75; Dako), a cell proliferation marker, and KRT8. 





Figure 5. Establishment of a humanised xenograft model of prostate cancer bone 
metastasis. A. Melt-electrospun tubular polycaprolactone scaffolds seeded with human 
osteoblasts and loaded with recombinant human BMP-7 were subcutaneously implanted into 
the flanks of male NOD/SCID mice. B. Micro-computed tomography 3D reconstruction 
demonstrates the development of a bone organ 14 weeks after implantation of the tissue-
engineered construct. Scale bar, 1 mm. C. Histological analysis (H/E) shows newly-formed 
bone matrix and a physiological bone marrow compartment with well-expanded sinusoids 
and haematopoietic cells of various lineages and differentiation stages. Scale bar, 50 µm. D. 
Immunostaining for human-specific NuMA proved that human-derived cells (brown staining) 
contributed to the formation of the bone microenvironment (murine cells stained blue with 
Mayer’s hematoxylin). Scale bar, 50 µm. E. Bioluminescence imaging after intracardiac 
injection of luciferase-labelled human PC-3 prostate cancer cells revealed a positive signal at 
the implanted bone construct (red circle) indicating homing of the cancer cells to the 
humanised bone. F. Micro-computed tomography 3D reconstruction shows an osteolytic 
growth pattern of the human prostate cancer metastases within the ossicles. Scale bar, 1 mm 
G. Staining for tartrate-resistant acid phosphatase (TRAP) confirmed these results by 
visualising a large number of osteoclasts (red staining) adjacent to tumour cells that degrade 
the bone matrix. Scale bar, 50 µm. H. Immunostaining for human-specific NuMA confirmed 
the presence of human prostate cancer cells (brown staining) scattered within the bone 





Figure 6. Effects of paclitaxel treatment seen in an intraperitoneal animal model using a 
bioengineered 3D construct. A. After 4 weeks of tumour growth within the intraperitoneal 
animal model, mice were treated with paclitaxel (10 mg/kg; DMSO as no treatment control) 
twice per week over 4 weeks. After 8 weeks, mice were sacrificed, and tumour tissues 
processed for subsequent analyses. The effect of treatment is indicated by H/E staining (top 
panel). Immunohistochemical analyses of PFA-fixed, paraffin-embedded ovarian cancer 
xenografts without and with paclitaxel administration indicate a reduced staining for the 
proliferation marker Ki67 and increased TUNEL staining (DeadEnd Colorimetric TUNEL 
System; Promega) upon treatment. Scale bars, 20 µm. B. To visualise the tumour vasculature, 
MICROFIL® (MV-122; Flow Tech Inc.) perfusions were carried out and were imaged by 
micro-computed tomography. The tumour vasculature was widely branched without 
treatment and dramatically reduced and less branched upon paclitaxel exposure. Scale bars, 1 
mm. C. To determine the biomechanic properties of healthy ovarian and tumour tissues, non-
fixed tissues underwent a confined compression test to measure the elastic modulus. The 
cancerous tissue was significantly stiffer than the non-malignant ovarian tissue. A further 
increase in tumour stiffness was detected upon paclitaxel treatment. D. This table summarises 
our reported treatment protocols and findings of ovarian cancer cells grown in vitro as 
monolayers (2D) and spheroids (3D) and in vivo in a spheroid-based animal model upon 
combined expression of the kallikrein-related peptidases (KLK) 4, KLK5, KLK6 and KLK7 
(KLK4-7). Cell monolayers expressing KLK4-7 were more resistant to paclitaxel treatment 
(media containing 10nM paclitaxel for 3 days) than vector controls. Spheroids grown over 7 
days and then treated with paclitaxel-containing media (10 nM) for another 7 days showed an 
enhanced cell survival, for both KLK4-7-expressing and KLK4-7-deficient cells. To validate 
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these in vitro effects upon paclitaxel treatment in vivo, the spheroid-based animal model, as 
described above, was used. Therefore, mice were treated with paclitaxel (10 mg/kg) 
intraperitoneally, twice per week, starting in week 4 over 4 weeks. Both KLK4-7-expressing 




Table 1: Hydrogel-based microenvironments for ovarian and prostate cancer. Examples 
for engineered biomaterial platforms for in vitro and in vivo applications are summarised. 
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Table 2. Engineered models for ovarian cancer. Examples for engineered culture 
techniques of ovarian cancer cells for in vitro and in vivo applications are summarised. 
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Table 3. Engineered models for prostate cancer. Examples for engineered culture 
techniques of prostate cancer cells for in vitro and in vivo applications are summarised. 
Microenvironment Cell line(s) In vitro In vivo Reference(s) Authors, 
Year 
3D co-cultures using 
normal prostate and 
cancer-associated 
fibroblasts for ECM 
production 




X  [12] Clark et al. 
2013 
3D co-cultures of 









LNCaP X  [20] Sieh et al. 
2012 
3D silk fibroin scaffolds PC-3 X  [51] Kwon et 
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coupled with BMP2 al. 2010 
bone marrow-derived 
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PC-3 X  [139] David et 
al. 2004 
3D cancer-bone metastasis 
model using murine 
calvarial bone organs 
co-cultured with 
prostate cancer cells 
in a roller tube system 
LNCaP; 
PC-3 
X  [186] Curtin et 
al. 2012 
Double layered, alginate 
hydrogel microspheres 
to co-culture cancer cells 




X  [187] Fang et al. 
2013 
3D rat tail collagen I-based 
co-cultures of cancer cells 






X  [188] Varzavand 
et al. 2013 
3D model of tumour-driven 
angiogenesis using human 
arterial rings co-cultured 
with cancer spheroids 
LNCaP X  [189] Seano et 
al. 2013 
3D porous chitosan-alginate 
scaffolds seeded with 
cancer cells and co-cultured 





X  [190] Florczyk et 
al. 2012 
Hydroxyapatite coated 
collagen I-based scaffolds 
seeded with human osteo- 
lasts and subcutaneously 
implanted into NOD/SCID 






Table 4. Measurement of cancer-associated protease activity in 3D. Examples for 
different techniques to measure the activity of cancer-associated proteases, including MMPs, 
cysteine and serine proteases, are summarised. 
Model Method Cancer 
type(s) 





Bioactivity assay Ovarian 
cancer 
MMP9 [15] Loessner et 
al. 2010 
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